Trial Outcomes & Findings for A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer (NCT NCT01420081)
NCT ID: NCT01420081
Last Updated: 2019-01-08
Results Overview
Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The outcome data table below presents the number of participants with clinical benefit response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
67 participants
Primary outcome timeframe
16 weeks from Cycle 1 Day 1
Results posted on
2019-01-08
Participant Flow
An open-label, Phase 2, four-arm, non-comparative study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of PF-04691502 (an oral PI3K/mTOR inhibitor) and PF-05212384 (an Intravenous \[IV\] Phosphoinositide 3-Kinase \[PI3K\]/Mammalian Target of Rapamycin \[mTOR\] inhibitor).
This study was conducted in parallel-arms in adult participants with recurrent endometrial cancer. Randomized arms included PF-05212384 (154mg dosage) and PF-04691502 (8mg which was lowered to 6mg) for both PI3K Basal or Activated. Lead-in Cohorts included PF-05212384 (89mg or 154mg) and PF-04691502 (4mg).
Participant milestones
| Measure |
PF-04691502 8 mg (PI3K Basal)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 8 mg orally, once daily (QD) until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Basal)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 8 mg (PI3K Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Basal)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, once weekly (Quaque, QW) until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
Lead-in-cohort (LIC) PF-04691502 (4 mg)
Participants who were enrolled in the PF-04691502 LIC began dosing with PF-04691502 4 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05691502 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (89 mg)
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 89 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (154 mg)
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 154 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
3
|
1
|
11
|
3
|
20
|
20
|
3
|
3
|
3
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
3
|
1
|
11
|
3
|
20
|
20
|
3
|
3
|
3
|
Reasons for withdrawal
| Measure |
PF-04691502 8 mg (PI3K Basal)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 8 mg orally, once daily (QD) until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Basal)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 8 mg (PI3K Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Basal)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, once weekly (Quaque, QW) until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
Lead-in-cohort (LIC) PF-04691502 (4 mg)
Participants who were enrolled in the PF-04691502 LIC began dosing with PF-04691502 4 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05691502 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (89 mg)
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 89 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (154 mg)
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 154 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Death
|
1
|
0
|
8
|
0
|
7
|
12
|
0
|
1
|
1
|
|
Overall Study
Lost to Follow-up
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
|
Overall Study
Study Terminated by Sponsor
|
2
|
1
|
1
|
3
|
11
|
7
|
3
|
2
|
2
|
|
Overall Study
Subject Refused Futher Follow-up
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Overall Study
Other Reasons
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Baseline characteristics by cohort
| Measure |
PF-04691502 8 mg (PI3K Basal)
n=3 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Basal)
n=1 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 8 mg (PI3K Activated)
n=11 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Activated)
n=3 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Basal)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Activated)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
Lead-in-cohort (LIC) PF-04691502 (4 mg)
n=3 Participants
Participants who were enrolled in the PF-04691502 LIC began dosing with PF-04691502 4 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05691502 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (89 mg)
n=3 Participants
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 89 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (154 mg)
n=3 Participants
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 154 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
Total
n=67 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Customized
< 18 years
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=8 Participants
|
0 participants
n=8 Participants
|
0 participants
n=24 Participants
|
0 participants
n=42 Participants
|
0 participants
n=42 Participants
|
|
Age, Customized
18 - 44 years
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=8 Participants
|
0 participants
n=8 Participants
|
1 participants
n=24 Participants
|
0 participants
n=42 Participants
|
1 participants
n=42 Participants
|
|
Age, Customized
45 - 64 years
|
2 participants
n=5 Participants
|
1 participants
n=7 Participants
|
4 participants
n=5 Participants
|
3 participants
n=4 Participants
|
9 participants
n=21 Participants
|
4 participants
n=8 Participants
|
2 participants
n=8 Participants
|
1 participants
n=24 Participants
|
2 participants
n=42 Participants
|
28 participants
n=42 Participants
|
|
Age, Customized
>= 65 years
|
1 participants
n=5 Participants
|
0 participants
n=7 Participants
|
7 participants
n=5 Participants
|
0 participants
n=4 Participants
|
11 participants
n=21 Participants
|
16 participants
n=8 Participants
|
1 participants
n=8 Participants
|
1 participants
n=24 Participants
|
1 participants
n=42 Participants
|
38 participants
n=42 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
20 Participants
n=21 Participants
|
20 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
67 Participants
n=42 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
PRIMARY outcome
Timeframe: 16 weeks from Cycle 1 Day 1Population: Per protocol dataset included participants enrolled for treatment, with baseline tumor, measurable disease and with disease under study. The LIC reporting arm were not a part of the per protocol analysis set for summarizing response.
Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The outcome data table below presents the number of participants with clinical benefit response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=4 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=11 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Clinical Benefit Response for PF-04691502
Participants with "No" response
|
3 Participants
|
11 Participants
|
—
|
|
Clinical Benefit Response for PF-04691502
Participants with "Yes" response
|
1 Participants
|
0 Participants
|
—
|
PRIMARY outcome
Timeframe: 16 weeks from Cycle 1 Day 1Population: Per protocol dataset included participants enrolled for treatment, with baseline tumor, measurable disease and with disease under study. The LIC reporting arm were not a part of the per protocol analysis set for summarizing response.
Clinical benefit response was defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks from Cycle 1 Day 1 (C1D1) to the first time of disease progression. The primary analysis is based on the clinical benefit rate which is calculated as proportion of participants with a clinical benefit response relative to total number of response evaluable participants. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions; SD does not qualify for CR, PR or Progression. All target lesions must be assessed. SD can follow PR only in the rare case that the sum increases by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds. A Clopper-Pearson exact 95% CI for the clinical benefit rate is presented in the below table.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=10 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=5 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=15 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Percentage of Participants With Clinical Benefit Response for PF-05212384
|
52.6 Percentage of participants
Interval 28.9 to 75.6
|
26.3 Percentage of participants
Interval 9.1 to 51.2
|
39.5 Percentage of participants
Interval 24.0 to 56.6
|
SECONDARY outcome
Timeframe: Randomization to objective progression, death or last tumor assessment without progression (up to 12 months)Population: Per protocol dataset included participants enrolled for treatment, with baseline tumor, measurable disease and with disease under study. The LIC reporting arm were not a part of the per protocol analysis set for summarizing response.
Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions. The outcome data table below presents the number of participants with objective response as "yes" or "no". On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=4 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=11 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Objective Response for PF-04691502
Participants with "Yes" response
|
0 Participants response
|
0 Participants response
|
—
|
|
Objective Response for PF-04691502
Participants with "No" response
|
4 Participants response
|
11 Participants response
|
—
|
SECONDARY outcome
Timeframe: Randomization to objective progression, death or last tumor assessment without progression (up to 12 months)Population: Per protocol dataset included participants enrolled for treatment, with baseline tumor, measurable disease and with disease under study. The LIC reporting arm were not a part of the per protocol analysis set for summarizing response.
Objective response is defined as CR or PR. CR: Complete response: 2 or more objective statuses of CR a minimum of 4 weeks apart documented before PD. Partial response: 2 or more objective statuses of PR or better a minimum of 4 weeks apart documented before PD, but not qualifying as CR. Per RECIST v1.1 for target lesions: CR defined as disappearance of all target lesions; PR defined as \>=30% decrease in the sum of the longest diameter of target lesions.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=38 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Percentage of Participants With Objective Response for PF-05212384
|
21.1 Percentage of participants
Interval 6.1 to 45.6
|
15.8 Percentage of participants
Interval 3.4 to 39.6
|
18.4 Percentage of participants
Interval 7.7 to 34.3
|
SECONDARY outcome
Timeframe: From Cycle 1 Day 1 to objective progressive disease or death due to any cause whichever occurs first (up to 12 months)Population: Per protocol dataset included participants enrolled for treatment, with baseline tumor, measurable disease and with disease under study. The LIC reporting arm were not a part of the per protocol analysis set for summarizing response.
PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions. On 09 Oct 2012, Pfizer decided to stop enrollment into PF-04691502. While tumor assessment for PF-04691502 was included as a listing in the final report, formal efficacy analysis for PF-04691502 was not performed.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=4 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=11 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Progression Free Survival for PF-04691502
Participant 8
|
0 Time to Event (Days)
|
1 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 11
|
0 Time to Event (Days)
|
53 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 12
|
0 Time to Event (Days)
|
105 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 13
|
0 Time to Event (Days)
|
1 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 3
|
50 Time to Event (Days)
|
0 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 4
|
199 Time to Event (Days)
|
0 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 1
|
1 Time to Event (Days)
|
0 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 2
|
108 Time to Event (Days)
|
0 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 5
|
0 Time to Event (Days)
|
54 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 6
|
0 Time to Event (Days)
|
55 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 7
|
0 Time to Event (Days)
|
51 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 9
|
0 Time to Event (Days)
|
54 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 10
|
0 Time to Event (Days)
|
62 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 14
|
0 Time to Event (Days)
|
54 Time to Event (Days)
|
—
|
|
Progression Free Survival for PF-04691502
Participant 15
|
0 Time to Event (Days)
|
54 Time to Event (Days)
|
—
|
SECONDARY outcome
Timeframe: From Cycle 1 Day 1 to objective progressive disease or death due to any cause whichever occurs first (up to 12 months)Population: Per protocol dataset included participants enrolled for treatment, with baseline tumor, measurable disease and with disease under study. The LIC reporting arm were not a part of the per protocol analysis set for summarizing response.
PFS is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the median. Approximate 95% confidence interval corresponding to this estimate was computed. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=38 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Progression Free Survival for PF-05212384
|
112.0 Days
Interval 59.0 to 167.0
|
89.0 Days
Interval 56.0 to 172.0
|
108.0 Days
Interval 62.0 to 149.0
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Per protocol dataset included participants enrolled for treatment, with baseline tumor, measurable disease and with disease under study. The LIC reporting arm were not a part of the per protocol analysis set for summarizing response.
Progression free survival is defined as the time from the date of cycle 1 day 1 to the date that objective progressive disease is documented or death due to any cause, whichever occurs first. PFS was characterized in terms of the probability of remaining progression-free at 6 months (based on Kaplan-Meier estimates). Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions with a minimum absolute increase of 5 mm, or an unequivocal progression of non-target lesion, or the appearance of new lesions.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=38 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Percentage of Participants With Progression Free Survival (PFS) at 6 Months for PF-05212384
|
23.2 Percentage of participants
Interval 7.3 to 44.1
|
25.0 Percentage of participants
Interval 7.8 to 47.2
|
24.3 Percentage of participants
Interval 11.6 to 39.5
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: Survival analysis was not performed as the study was terminated early. No data are available because data were not collected. The LIC reporting arm were not a part of the per protocol analysis set for summarizing response.
OS is defined as the time from the date of Cycle 1 Day 1 to the date of death.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 daysPopulation: Participants were analyzed on PD analysis set which consisted of all enrolled patients who started treatment and had a baseline as well as at least one post-baseline measurement for at least one PD biomarker. The PD biomarkers include serum glucose, insulin, HbA1c, cholesterol, and triglycerides.
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=18 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=18 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=36 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
Cycle 1 Day 15 (n=18,17,35)
|
105.3 Glucose (mg/dL)
Standard Deviation 18.44
|
117.2 Glucose (mg/dL)
Standard Deviation 61.04
|
111.1 Glucose (mg/dL)
Standard Deviation 44.26
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
Cycle 2 Day 15 (n=17,8,25)
|
104.8 Glucose (mg/dL)
Standard Deviation 13.94
|
106.4 Glucose (mg/dL)
Standard Deviation 19.36
|
105.3 Glucose (mg/dL)
Standard Deviation 15.47
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
Baseline
|
98.5 Glucose (mg/dL)
Standard Deviation 12.76
|
101.7 Glucose (mg/dL)
Standard Deviation 26.56
|
100.1 Glucose (mg/dL)
Standard Deviation 20.60
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
Cycle 1 Day 22 (n=2,1,3)
|
103.0 Glucose (mg/dL)
Standard Deviation 16.34
|
120.1 Glucose (mg/dL)
Standard Deviation 0
|
108.7 Glucose (mg/dL)
Standard Deviation 15.19
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
Cycle 2 Day 1 (n=17,14,31)
|
103.7 Glucose (mg/dL)
Standard Deviation 19.31
|
114.0 Glucose (mg/dL)
Standard Deviation 39.42
|
108.3 Glucose (mg/dL)
Standard Deviation 29.99
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
Cycle 3 Day 1 (n=14,10,24)
|
100.6 Glucose (mg/dL)
Standard Deviation 16.29
|
125.9 Glucose (mg/dL)
Standard Deviation 74.50
|
111.1 Glucose (mg/dL)
Standard Deviation 49.85
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
Cycle 4 Day 1 (n=12,7,19)
|
96.3 Glucose (mg/dL)
Standard Deviation 10.40
|
98.9 Glucose (mg/dL)
Standard Deviation 10.20
|
97.3 Glucose (mg/dL)
Standard Deviation 10.12
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glucose (mg/dL)
Cycle 5 Day 1 (n=9,4,13)
|
103.2 Glucose (mg/dL)
Standard Deviation 15.17
|
112.2 Glucose (mg/dL)
Standard Deviation 24.37
|
106.0 Glucose (mg/dL)
Standard Deviation 17.90
|
SECONDARY outcome
Timeframe: Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 daysPopulation: Participants were analyzed on PD analysis set which consisted of all enrolled patients who started treatment and had a baseline as well as at least one post-baseline measurement for at least one PD biomarker. The PD biomarkers include serum glucose, insulin, HbA1c, cholesterol, and triglycerides.
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=17 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=14 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=31 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
Cycle 2 Day 15 (n=14,6,20)
|
28.2 Insulin (UIU/mL)
Standard Deviation 29.56
|
21.9 Insulin (UIU/mL)
Standard Deviation 10.49
|
26.3 Insulin (UIU/mL)
Standard Deviation 25.21
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
Cycle 1 Day 22 (n=2,1,3)
|
57.6 Insulin (UIU/mL)
Standard Deviation 51.18
|
29.1 Insulin (UIU/mL)
Standard Deviation 0
|
48.1 Insulin (UIU/mL)
Standard Deviation 39.75
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
Cycle 2 Day 1 (n=17,10,27)
|
30.3 Insulin (UIU/mL)
Standard Deviation 28.92
|
28.9 Insulin (UIU/mL)
Standard Deviation 27.85
|
29.8 Insulin (UIU/mL)
Standard Deviation 27.99
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
Cycle 3 Day 1 (n=13,9,22)
|
20.7 Insulin (UIU/mL)
Standard Deviation 13.65
|
35.1 Insulin (UIU/mL)
Standard Deviation 38.66
|
26.6 Insulin (UIU/mL)
Standard Deviation 26.99
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
Cycle 4 Day 1 (n=11,6,17)
|
17.1 Insulin (UIU/mL)
Standard Deviation 10.04
|
24.8 Insulin (UIU/mL)
Standard Deviation 32.32
|
19.8 Insulin (UIU/mL)
Standard Deviation 20.10
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
Cycle 5 Day 1 (n=7,4,11)
|
17.0 Insulin (UIU/mL)
Standard Deviation 15.56
|
15.7 Insulin (UIU/mL)
Standard Deviation 6.20
|
16.5 Insulin (UIU/mL)
Standard Deviation 12.54
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
Baseline
|
15.2 Insulin (UIU/mL)
Standard Deviation 12.68
|
14.4 Insulin (UIU/mL)
Standard Deviation 7.03
|
14.8 Insulin (UIU/mL)
Standard Deviation 10.36
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Insulin (UIU/mL)
Cycle 1 Day 15 (n=16,12,28)
|
23.6 Insulin (UIU/mL)
Standard Deviation 14.69
|
35.9 Insulin (UIU/mL)
Standard Deviation 37.05
|
28.9 Insulin (UIU/mL)
Standard Deviation 26.79
|
SECONDARY outcome
Timeframe: Baseline (Day -3) and Cycle1 to Cycle 5 where each cycle consist of 28 daysPopulation: participants were analyzed on PD analysis set which consisted of all enrolled patients who started treatment and had a baseline as well as at least one post-baseline measurement for at least one PD biomarker. The PD biomarkers include serum glucose, insulin, HbA1c, cholesterol, and triglycerides.
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=18 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=18 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=36 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)
Baseline (n=15,14,29)
|
7.8 HbA1c (mg/dL)
Standard Deviation 8.58
|
7.5 HbA1c (mg/dL)
Standard Deviation 6.15
|
7.7 HbA1c (mg/dL)
Standard Deviation 7.37
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)
Cycle 1 Day 15 (n=4,2,6)
|
14.7 HbA1c (mg/dL)
Standard Deviation 19.00
|
7.1 HbA1c (mg/dL)
Standard Deviation 1.34
|
12.2 HbA1c (mg/dL)
Standard Deviation 15.25
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)
Cycle 2 Day 1 (n=15,13,28)
|
8.4 HbA1c (mg/dL)
Standard Deviation 9.66
|
6.7 HbA1c (mg/dL)
Standard Deviation 1.16
|
7.6 HbA1c (mg/dL)
Standard Deviation 7.05
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)
Cycle 2 Day 15 (n=3,0,3)
|
6.7 HbA1c (mg/dL)
Standard Deviation 0.71
|
NA HbA1c (mg/dL)
Standard Deviation NA
None of the participants were analyzed for arm PF-05212384 (PI3K activated) and hence data is not available.
|
6.7 HbA1c (mg/dL)
Standard Deviation 0.71
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)
Cycle 3 Day 1 (n=10,4,14)
|
6.0 HbA1c (mg/dL)
Standard Deviation 0.78
|
7.3 HbA1c (mg/dL)
Standard Deviation 1.70
|
6.4 HbA1c (mg/dL)
Standard Deviation 1.19
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)
Cycle 4 Day 1 (n=12,7,19)
|
8.9 HbA1c (mg/dL)
Standard Deviation 10.13
|
6.9 HbA1c (mg/dL)
Standard Deviation 1.05
|
8.2 HbA1c (mg/dL)
Standard Deviation 8.01
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Glycosylated Hemoglobin (HbA1c)
Cycle 5 Day 1 (n=8,2,10)
|
5.9 HbA1c (mg/dL)
Standard Deviation 0.89
|
31.5 HbA1c (mg/dL)
Standard Deviation 36.06
|
11.0 HbA1c (mg/dL)
Standard Deviation 16.17
|
SECONDARY outcome
Timeframe: Baseline (Day -3) and Cycle1 to Cycle 3 where each cycle consist of 28 daysPopulation: Participants were analyzed on PD analysis set which consisted of all enrolled patients who started treatment and had a baseline as well as at least one post-baseline measurement for at least one PD biomarker. The PD biomarkers include serum glucose, insulin, HbA1c, cholesterol, and triglycerides.
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=18 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=18 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=36 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Cholesterol (mg/dL)
Baseline (n=11,4,15)
|
213 Cholesterol (mg/dL)
Standard Deviation 54.48
|
186.5 Cholesterol (mg/dL)
Standard Deviation 52.43
|
205.9 Cholesterol (mg/dL)
Standard Deviation 53.45
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Cholesterol (mg/dL)
Cycle 1 Day 28 (n=15,7,22)
|
214.9 Cholesterol (mg/dL)
Standard Deviation 49.15
|
161.6 Cholesterol (mg/dL)
Standard Deviation 86.51
|
198.0 Cholesterol (mg/dL)
Standard Deviation 66.28
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Cholesterol (mg/dL)
Cycle 2 Day 28 (n=16,6,22)
|
229.8 Cholesterol (mg/dL)
Standard Deviation 44.31
|
127.9 Cholesterol (mg/dL)
Standard Deviation 108.69
|
202.0 Cholesterol (mg/dL)
Standard Deviation 79.83
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Cholesterol (mg/dL)
Cycle 3 Day 28 (n=11,4,15)
|
230.5 Cholesterol (mg/dL)
Standard Deviation 48.63
|
137.6 Cholesterol (mg/dL)
Standard Deviation 107.02
|
205.7 Cholesterol (mg/dL)
Standard Deviation 77.15
|
SECONDARY outcome
Timeframe: Baseline (Day -3) and Cycle1 to Cycle 3 where each cycle consist of 28 daysPopulation: Participants were analyzed on PD analysis set which consisted of all enrolled patients who started treatment and had a baseline as well as at least one post-baseline measurement for at least one PD biomarker. The PD biomarkers include serum glucose, insulin, HbA1c, cholesterol, and triglycerides.
PD biomarkers are measured at screening (baseline) and multiple time points post baseline. Baseline is defined as the last measurement prior to dosing, which is the measurement at screening or the cycle 1 day 1 pre-dose measurement if collected. This outcome measure will be updated once the data is available with the supplemental clinical study report.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=18 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=18 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=36 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Triglycerides (mg/dL)
Baseline (n=11,4,15)
|
104.2 Triglycerides (mg/dL)
Standard Deviation 40.95
|
133.4 Triglycerides (mg/dL)
Standard Deviation 25.75
|
112.0 Triglycerides (mg/dL)
Standard Deviation 38.96
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Triglycerides (mg/dL)
Cycle 1 Day 28 (n=15,7,22)
|
136.9 Triglycerides (mg/dL)
Standard Deviation 70.03
|
134.5 Triglycerides (mg/dL)
Standard Deviation 57.21
|
136.1 Triglycerides (mg/dL)
Standard Deviation 64.85
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Triglycerides (mg/dL)
Cycle 2 Day 28 (n=16,6,22)
|
133.2 Triglycerides (mg/dL)
Standard Deviation 71.40
|
117.1 Triglycerides (mg/dL)
Standard Deviation 62.77
|
128.8 Triglycerides (mg/dL)
Standard Deviation 68.07
|
|
Level of Each Pharmacodynamic Parameter at Specified Timepoints- Triglycerides (mg/dL)
Cycle 3 Day 28 (n=10,4,14)
|
119.9 Triglycerides (mg/dL)
Standard Deviation 64.22
|
130.4 Triglycerides (mg/dL)
Standard Deviation 58.01
|
122.9 Triglycerides (mg/dL)
Standard Deviation 60.47
|
SECONDARY outcome
Timeframe: Prior to Cycle 1 Day 1Population: Participants were analyzed as the molecular profiling tumor analysis set was defined as all enrolled patients who started treatment and had baseline tumor tissues (archived paraffin block or unstained slides or fresh tumor tissue sample) successfully analyzed for at least one of the biomarkers.
Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, PTEN protein levels, and PIK3CA gene amplification were to be assessed. Each slide was imaged by whole slide scanning and patient samples were scored as follows: * Pathologist manual score (0, 1+, 2+, 3+) for overall staining intensity of tumor tissue. * Percentage of positive tumor cells staining at 0, 1+, 2+, and 3+. * H-score value (integer between 0 and 300) for tumor cell staining was calculated. The higher the stathmin staining, the higher the stathmin H-score.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=21 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=40 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Stathmin H Score [Mean (SD)] for Each Treatment Arm With Gene and/or Protein Expression Biomarkers in Biopsied Tumor Tissue
|
96.4 Score
Standard Deviation 33.76
|
201.3 Score
Standard Deviation 34.87
|
146.2 Score
Standard Deviation 62.9
|
SECONDARY outcome
Timeframe: Baseline and Cycle1 to Cycle 5 where each cycle consist of 28 daysPopulation: Participants were analyzed as the molecular profiling tumor analysis set was defined as all enrolled patients who started treatment and had baseline tumor tissues (archived paraffin block or unstained slides or fresh tumor tissue sample) successfully analyzed for at least one of the biomarkers.
Gene and/or protein expression biomarkers in biopsied tumor tissue relating to PI3K and/or mTOR pathway activation, such as PIK3CA and PIK3R1 mutations, Phosphatase And Tensin Homolog (PTEN) protein levels, and PIK3CA gene amplification were to be assessed. Stained tissues were evaluated by a board-certified pathologist who provided a manual pathology score (i.e., 0, 1+, 2+, or 3+) and, if appropriate, comments upon the staining of the specimen. The directionality increases from 0 to 3+ with 0 being no staining for PTEN by IHC and 3+ being high staining intensity for PTEN.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=21 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=40 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
PIK3CA Amplification, Nonamplified (n=17,15,32)
|
94.1 Percentage of participants
|
93.3 Percentage of participants
|
93.8 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
PIK3CA Amplification, Amplified (n=17,15,32)
|
5.9 Percentage of participants
33.76
|
6.7 Percentage of participants
34.87
|
6.3 Percentage of participants
62.9
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
KRAS Mutation, Positive (n=21,18,39)
|
19.0 Percentage of participants
|
5.6 Percentage of participants
|
12.8 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
KRAS Mutation, Negative (n=21,18,39)
|
81.0 Percentage of participants
|
94.4 Percentage of participants
|
87.2 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
KRAS Mutation OBSV, Gly12Asp (n=4,1,5)
|
25.0 Percentage of participants
|
100 Percentage of participants
|
40.0 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
KRAS Mutation OBSV, Gly12Cys (n=4,1,5)
|
25.0 Percentage of participants
|
0 Percentage of participants
|
20.0 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
KRAS Mutation OBSV, Gly12Val (n=4,1,5)
|
50.0 Percentage of participants
|
0 Percentage of participants
|
40.0 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
PTEN Stroma Manual Score, 1+ (n=21,19,40)
|
4.8 Percentage of participants
|
0 Percentage of participants
|
2.5 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
PTEN Stroma Manual Score, 2+ (n=21,19,40)
|
28.6 Percentage of participants
|
26.3 Percentage of participants
|
27.5 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
PTEN Stroma Manual Score, 3+ (n=21,19,40)
|
66.7 Percentage of participants
|
73.7 Percentage of participants
|
70.0 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
PTEN Tumor Manual Score, 0 (n=21,19,40)
|
23.8 Percentage of participants
|
21.1 Percentage of participants
|
22.5 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
PTEN Tumor Manual Score, 1+ (n=21,19,40)
|
38.1 Percentage of participants
|
31.6 Percentage of participants
|
35.0 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
PTEN Tumor Manual Score, 2+ (n=21,19,40)
|
38.1 Percentage of participants
|
47.4 Percentage of participants
|
42.5 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
KRAS SCC, Acceptable (n=21,18,39)
|
100 Percentage of participants
|
100 Percentage of participants
|
100 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
Stathmin H/L,Tissue, High (n=21,19,40)
|
0 Percentage of participants
|
100 Percentage of participants
|
47.5 Percentage of participants
|
|
Percentage of Participants in Each Treatment Arm With Gene and/or Protein Expression Biomarkers- PIK3CA Amplification, KRAS Mutation P/N, KRAS Mutation OBSV, PTEN Stroma Manual Score, PTEN Tumor Manual Score, KRAS SCC and Stathmin H/L,Tissue.
Stathmin H/L,Tissue, Low (n=21,19,40)
|
100 Percentage of participants
|
0 Percentage of participants
|
52.5 Percentage of participants
|
SECONDARY outcome
Timeframe: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1Population: Participants were analyzed on PK parameter analysis set which was defined as all treated patients who had at least one of the PK parameters of interest estimated.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=15 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Area Under the Serum Concentration Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of PF-05212384 at Each Specified Time Points.
|
15280 ng.hr/mL
Geometric Coefficient of Variation 24
|
14870 ng.hr/mL
Geometric Coefficient of Variation 40
|
—
|
SECONDARY outcome
Timeframe: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1Population: Participants were analyzed on PK parameter analysis set which was defined as all treated patients who had at least one of the PK parameters of interest estimated.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=15 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Area Under the Serum Concentration Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-05212384 at Each Specified Time Points.
|
15080 ng.hr/mL
Geometric Coefficient of Variation 24
|
15890 ng.hr/mL
Geometric Coefficient of Variation 52
|
—
|
SECONDARY outcome
Timeframe: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1Population: Participants were analyzed on PK parameter analysis set which was defined as all treated patients who had at least one of the PK parameters of interest estimated.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=15 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Maximum Plasma Concentration (Cmax) of PF-05212384 at Each Specified Time Points.
|
9078 ng/mL
Geometric Coefficient of Variation 36
|
7057 ng/mL
Geometric Coefficient of Variation 84
|
—
|
SECONDARY outcome
Timeframe: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1Population: Participants were analyzed on PK parameter analysis set which was defined as all treated patients who had at least one of the PK parameters of interest estimated.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=15 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Terminal Elimination Half Life (t½) of PF-05212384 at Each Specified Time Points.
|
35.02 hours
Standard Deviation 5.32
|
34.09 hours
Standard Deviation 8.87
|
—
|
SECONDARY outcome
Timeframe: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1Population: Participants were analyzed on PK parameter analysis set which was defined as all treated patients who had at least one of the PK parameters of interest estimated.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=15 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Time for Cmax (Tmax) of PF-05212384 at Each Specified Time Points.
|
0.525 hours
Interval 0.5 to 1.07
|
0.650 hours
Interval 0.5 to 1.08
|
—
|
SECONDARY outcome
Timeframe: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hours at Day 1Population: Participants were analyzed on PK parameter analysis set which was defined as all treated patients who had at least one of the PK parameters of interest estimated.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=15 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Clearance (CL) of PF-05212384 at Each Specified Time Points.
|
10.09 L/hr
Geometric Coefficient of Variation 24
|
10.36 L/hr
Geometric Coefficient of Variation 40
|
—
|
SECONDARY outcome
Timeframe: Pre-dose: 0 hours, and Post dose: 0.5 (after end of infusion), 1, 2, 4, 6, 24, 72, and 120 hoursPopulation: Participants were analyzed on PK parameter analysis set which was defined as all treated patients who had at least one of the PK parameters of interest estimated.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=19 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=15 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Steady State Volume of Distribution (Vss) of PF-05212384 at Each Specified Time Points.
|
165.6 Litres
Geometric Coefficient of Variation 32
|
174.9 Litres
Geometric Coefficient of Variation 57
|
—
|
SECONDARY outcome
Timeframe: From baseline (-3 days) until 35 days post last dosePopulation: Participants were analyzed on safety analysis set which was defined as all enrolled patients who started treatment.
Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=40 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Number of Treatment-emergent Adverse Events (TEAEs) - All Causalities
|
244 Number of AEs
|
269 Number of AEs
|
513 Number of AEs
|
SECONDARY outcome
Timeframe: From baseline (-3 days) until 35 days post last dosePopulation: Participants were analyzed on safety analysis set which was defined as all enrolled patients who started treatment.
Safety of participants in terms of TEAEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=40 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Participants with AEs
|
21 Number of participants
|
18 Number of participants
|
39 Number of participants
|
|
Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Participants with Serious Adverse Events (SAEs)
|
3 Number of participants
|
10 Number of participants
|
13 Number of participants
|
|
Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Participants with Grade 3 or Grade 4 AEs
|
7 Number of participants
|
14 Number of participants
|
21 Number of participants
|
|
Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Participants with Grade 5 AEs
|
1 Number of participants
|
1 Number of participants
|
2 Number of participants
|
|
Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Permanently Discontinued due to AEs
|
1 Number of participants
|
5 Number of participants
|
6 Number of participants
|
|
Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Dose Reduced due to AEs
|
1 Number of participants
|
5 Number of participants
|
6 Number of participants
|
|
Summary of Treatment-emergent Adverse Events (TEAEs) - All Causalities
Temporary Discontinuations due to AEs
|
8 Number of participants
|
10 Number of participants
|
16 Number of participants
|
SECONDARY outcome
Timeframe: From baseline (-3 days) until 35 days post last dosePopulation: Participants were analyzed on safety analysis set which was defined as all enrolled patients who started treatment.
Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=40 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Number of Treatment-related TEAEs
|
158 Number of AEs
|
161 Number of AEs
|
319 Number of AEs
|
SECONDARY outcome
Timeframe: From baseline (-3 days) until 35 days post last dosePopulation: Participants were analyzed on safety analysis set which was defined as all enrolled patients who started treatment.
Safety of subject in terms of number of participants with treatment related AEs. Note: One subject treated with PF-05212384 had the stathmin status changed after randomization and was categorized under the corresponding arm.
Outcome measures
| Measure |
PF-04691502 (PI3K Basal)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 (PI3K Activated)
n=20 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 (PI3K Basal + Activated)
n=3 Participants
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal + activated). Participants were given PF-05212384 QW (Days 1, 8, 15 and 22 of each cycle), with a ±3 day window.
|
|---|---|---|---|
|
Summary of Treatment-related TEAEs
Participants with AEs
|
21 Number of participants
|
18 Number of participants
|
39 Number of participants
|
|
Summary of Treatment-related TEAEs
Participants with SAEs
|
0 Number of participants
|
3 Number of participants
|
3 Number of participants
|
|
Summary of Treatment-related TEAEs
Participants with Grade 3 or Grade 4 AEs
|
4 Number of participants
|
9 Number of participants
|
13 Number of participants
|
|
Summary of Treatment-related TEAEs
Participants with Grade 5 AEs
|
0 Number of participants
|
0 Number of participants
|
0 Number of participants
|
|
Summary of Treatment-related TEAEs
Permanently Discontinued due to AEs
|
1 Number of participants
|
2 Number of participants
|
3 Number of participants
|
|
Summary of Treatment-related TEAEs
Dose Reduced due to AEs
|
1 Number of participants
|
4 Number of participants
|
5 Number of participants
|
|
Summary of Treatment-related TEAEs
Temporary Discontinuations due to AEs
|
6 Number of participants
|
7 Number of participants
|
13 Number of participants
|
Adverse Events
PF-04691502 8 mg (PI3K Basal)
Serious events: 3 serious events
Other events: 5 other events
Deaths: 0 deaths
PF-04691502 6 mg (PI3K Basal)
Serious events: 1 serious events
Other events: 1 other events
Deaths: 0 deaths
PF-04691502 8 mg (PI3K Activated)
Serious events: 7 serious events
Other events: 9 other events
Deaths: 0 deaths
PF-04691502 6 mg (PI3K Activated)
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
PF-05212384 154 mg (PI3K Basal)
Serious events: 3 serious events
Other events: 21 other events
Deaths: 0 deaths
PF-05212384 154 mg (PI3K Activated)
Serious events: 10 serious events
Other events: 18 other events
Deaths: 0 deaths
Lead-in-cohort (LIC) PF-04691502 (4 mg)
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
LIC PF-05212384 (89 mg)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LIC PF-05212384 (154 mg)
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
PF-04691502 8 mg (PI3K Basal)
n=5 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Basal)
n=1 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 8 mg (PI3K Activated)
n=9 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Activated)
n=3 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Basal)
n=21 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW (Quaque \[Once Weekly\]) until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Activated)
n=19 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
Lead-in-cohort (LIC) PF-04691502 (4 mg)
n=3 participants at risk
Participants who were enrolled in the PF-04691502 LIC began dosing with PF-04691502 4 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05691502 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (89 mg)
n=3 participants at risk
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 89 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (154 mg)
n=3 participants at risk
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 154 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Cardiac Failure
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Diarrhoea
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Large Intestinal Obstruction
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Oral Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Chills
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Disease Progression
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Lung Infection
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Pneumocystis Jirovecii Pneumonia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Pneumonia
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Skin Infection
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Urinary Tract Infection
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Lymphocyte Count Decreased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Diabetic Ketoacidosis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Fistula
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric Cancer
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Cerebrovascular Accident
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Renal and urinary disorders
Acute Kidney Injury
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Renal and urinary disorders
Urinary Tract Obstruction
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Acute Respiratory Distress Syndrome
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia Aspiration
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
40.0%
2/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax Spontaneous
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary Embolism
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Vascular disorders
Deep Vein Thrombosis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
Other adverse events
| Measure |
PF-04691502 8 mg (PI3K Basal)
n=5 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Basal)
n=1 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-04691502 8 mg (PI3K Activated)
n=9 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose.
|
PF-04691502 6 mg (PI3K Activated)
n=3 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Basal)
n=21 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW (Quaque \[Once Weekly\]) until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
PF-05212384 154 mg (PI3K Activated)
n=19 participants at risk
Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
Lead-in-cohort (LIC) PF-04691502 (4 mg)
n=3 participants at risk
Participants who were enrolled in the PF-04691502 LIC began dosing with PF-04691502 4 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05691502 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (89 mg)
n=3 participants at risk
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 89 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
LIC PF-05212384 (154 mg)
n=3 participants at risk
Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 154 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death.
|
|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Cardiac disorders
Sinus Tachycardia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Ear and labyrinth disorders
Ear Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Ear and labyrinth disorders
External Ear Inflammation
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Eye disorders
Abnormal Sensation In Eye
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Eye disorders
Eyelid Bleeding
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Eye disorders
Iritis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Eye disorders
Vision Blurred
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Eye disorders
Visual Impairment
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Abdominal Discomfort
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Abdominal Distension
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Abdominal Pain
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
21.1%
4/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Abdominal Pain Lower
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Abdominal Pain Upper
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Aphthous Stomatitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Ascites
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Cheilitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Constipation
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
3/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
7/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
31.6%
6/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Diarrhoea
|
80.0%
4/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
77.8%
7/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
38.1%
8/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
52.6%
10/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Dry Mouth
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
21.1%
4/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
26.3%
5/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Gastrooesophageal Reflux Disease
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Glossodynia
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Hyperchlorhydria
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Hypoaesthesia Oral
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Lip Ulceration
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Mouth Ulceration
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Nausea
|
60.0%
3/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
55.6%
5/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
57.1%
12/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
52.6%
10/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
3/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
3/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Odynophagia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Oral Discomfort
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Oral Dysaesthesia
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Oral Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Rectal Haemorrhage
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Stomatitis
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
44.4%
4/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
23.8%
5/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
3/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
3/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Tooth Disorder
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
7/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
36.8%
7/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Asthenia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
3/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
7/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Catheter Site Bruise
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Catheter Site Oedema
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Catheter Site Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Infusion Site Extravasation
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Chills
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Fatigue
|
60.0%
3/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
6/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
23.8%
5/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
52.6%
10/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Gait Disturbance
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Influenza Like Illness
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Infusion Site Rash
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Malaise
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Medical Device Complication
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Mucosal Dryness
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Mucosal Inflammation
|
40.0%
2/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
3/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
57.1%
12/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
42.1%
8/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Non-Cardiac Chest Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Oedema
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Oedema Peripheral
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
26.3%
5/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
General disorders
Pyrexia
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Hepatobiliary disorders
Hepatotoxicity
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Bacteriuria
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Candida Infection
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Injury, poisoning and procedural complications
Pelvic Fracture
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Cystitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Folliculitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Fungal Skin Infection
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Genital Herpes Zoster
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Gingivitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Oral Candidiasis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Oral Fungal Infection
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Oral Herpes
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Paronychia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Pneumocystis Jirovecii Pneumonia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Respiratory Tract Infection
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Rhinitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Skin Infection
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Upper Respiratory Tract Infection
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Urinary Tract Infection
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
26.3%
5/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Vulvitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Injury, poisoning and procedural complications
Infusion Related Reaction
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Injury, poisoning and procedural complications
Limb Injury
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Injury, poisoning and procedural complications
Vascular Access Complication
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Alanine Aminotransferase Increased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Aspartate Aminotransferase Increased
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Blood Alkaline Phosphatase
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Blood Alkaline Phosphatase Increased
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Blood Cholesterol Increased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Blood Creatinine
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Blood Lactate Dehydrogenase Increased
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Blood Magnesium Decreased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Blood Pressure Diastolic Increased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Blood Triglycerides Increased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Chest X-Ray Abnormal
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Electrocardiogram Qt Prolonged
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Glycosylated Haemoglobin Increased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Haemoglobin
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Lymphocyte Count Decreased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Neutrophil Count Decreased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Platelet Count Decreased
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Weight Decreased
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
White Blood Cell Count Decreased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Decreased Appetite
|
40.0%
2/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
6/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
42.9%
9/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
42.1%
8/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Dehydration
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Diabetes Mellitus
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
100.0%
5/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
77.8%
7/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
19.0%
4/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
21.1%
4/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
44.4%
4/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
44.4%
4/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
40.0%
2/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
21.1%
4/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Back Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Fistula
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Inguinal Mass
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Muscle Spasms
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal Chest Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Osteopenia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Musculoskeletal and connective tissue disorders
Pain In Extremity
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oncologic Complication
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Ageusia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Amnesia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Dizziness
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Dysgeusia
|
40.0%
2/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
28.6%
6/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
42.1%
8/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Headache
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Hypersomnia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Sciatica
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
21.1%
4/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Nervous system disorders
Syncope
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Bradyphrenia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Confusional State
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Depression
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Dysthymic Disorder
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Hallucination, Visual
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Irritability
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Psychiatric disorders
Restlessness
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Renal and urinary disorders
Renal Colic
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Renal and urinary disorders
Urinary Incontinence
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Renal and urinary disorders
Urinary Retention
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Renal and urinary disorders
Urinary Tract Obstruction
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Reproductive system and breast disorders
Pelvic Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Reproductive system and breast disorders
Vaginal Haemorrhage
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Reproductive system and breast disorders
Vulvovaginal Discomfort
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Catarrh
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
7/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
3/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea Exertional
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal Pain
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
3/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural Effusion
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Productive Cough
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinalgia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-Airway Cough Syndrome
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
14.3%
3/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Dermatitis Contact
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Dry Skin
|
40.0%
2/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Hangnail
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
3/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Ingrowing Nail
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Nail Disorder
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Night Sweats
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Onycholysis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Pain Of Skin
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Palmar-Plantar Erythrodysaesthesia Syndrome
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Papule
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
40.0%
2/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Purpura
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Rash
|
40.0%
2/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
22.2%
2/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
28.6%
6/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
15.8%
3/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
3/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
66.7%
2/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Rash Generalised
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Rash Maculo-Papular
|
20.0%
1/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
26.3%
5/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Rash Papular
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Skin Disorder
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Skin Exfoliation
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Skin Lesion
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Swelling Face
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
100.0%
1/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Vascular disorders
Haematoma
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Vascular disorders
Hot Flush
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Vascular disorders
Hypertension
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
19.0%
4/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Vascular disorders
Hypotension
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Vascular disorders
Lymphoedema
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Vascular disorders
Pallor
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Investigations
Blood Creatinine Increased
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
9.5%
2/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
10.5%
2/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Vascular disorders
Phlebitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
11.1%
1/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Eye disorders
Dry Eyes
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
33.3%
1/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Gastrointestinal disorders
Noninfective Gingivitis
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Herpes Zoster
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
4.8%
1/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.00%
0/5 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/1 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/9 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/21 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
5.3%
1/19 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
0.00%
0/3 • Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.
There are inconsistency with the number of paticipants per arm in 'Participant flow section' and 'AE section' (both tables). This was because one participant treated with PF-05212384 and two subjects treated with PF-04691502 had their stathmin status changed after randomization and are categorized under the corresponding arm.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
- Publication restrictions are in place
Restriction type: OTHER